PRR25: A Potential Drug Target for Various Diseases (G388199)

Target Name: PRR25

NCBI ID: G388199

PRR25

PRR25: A Potential Drug Target for Various Diseases

PRR25, also known as PR25-HUMAN, is a protein that is expressed in human tissues and has been identified as a potential drug target in the treatment of various diseases, including cancer. The protein is derived from the human placenta, and its unique structure and expression have led to its potential as a drug target.

The PRR25 protein is a type of RNA-protein hybrid, which means it consists of both RNA and protein components. The RNA component of PRR25 is derived from the gene E1, which is located on chromosome 16 and has been shown to play a role in the development and maintenance of placenta. The protein component of PRR25 is derived from the gene F1, which is located on chromosome 11 and has been shown to be involved in the regulation of various cellular processes, including cell adhesion, migration, and invasion.

PRR25 is expressed in various human tissues, including the placenta, brain, heart, and liver. It is shown to be involved in the development and maintenance of the placenta, which is responsible for providing oxygen and nutrients to the developing fetus. The expression of PRR25 in the placenta has also been shown to be involved in the regulation of pregnancy outcomes, including pregnancy length, weight, and the risk of preterm delivery.

In addition to its role in the placenta, PRR25 is also expressed in other tissues and has been shown to be involved in various cellular processes, including cell adhesion, migration, and invasion. Its expression has been shown to be involved in the regulation of tissue repair and regeneration, as well as the development and progression of cancer.

The potential drug target status of PRR25 is due to its unique structure and expression. Its RNA-protein hybrid structure and the fact that it is expressed in various human tissues make it an attractive target for drugs that can modulate its expression and activity. Additionally, its involvement in various cellular processes and its expression in different tissues make it a promising target for drugs that can affect its levels or activity in specific tissues.

One of the main advantages of PRR25 as a drug target is its accessibility. Its expression is found in various human tissues, making it an attractive target for drugs that can affect its levels or activity in those tissues. Additionally, its accessibility makes it easier to study its function and how it interacts with other molecules.

Another advantage of PRR25 as a drug target is its potential to be a once-weekly drug. Its expression is found in various human tissues, including the placenta, which means that a drug that can modulate its expression can be administered once a week, rather than daily or multiple times a week. This is important for reducing the potential side effects associated with frequent drug administration.

PRR25 has also been shown to be involved in various signaling pathways, which makes it an attractive target for drugs that can modulate its activity. Its expression has been shown to be involved in the PI3K/Akt signaling pathway, which is involved in the regulation of cellular processes such as cell adhesion, migration, and invasion. Additionally, its expression has been shown to be involved in the TGF-β signaling pathway, which is involved in the regulation of cell growth, differentiation, and repair.

In conclusion, PRR25 is a protein that has been identified as a potential drug target due to its unique structure and expression. Its expression in various human tissues and its involvement in various cellular processes make it an attractive target for drugs that can modulate its activity. Additionally, its accessibility and potential to be a once-weekly drug make it an attractive target for the treatment of various diseases. Further research is needed to fully understand its function and potential as a drug target.

Protein Name: Proline Rich 25

The "PRR25 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PRR25 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets